IDEXX Laboratories stock gains after double digit Q2 growth and raised guidance

Published on 09/21/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock recently closed at just over USD 511 on September 18, 2026 after the company reported double digit Q2 2026 growth and raised its full year guidance. The stock’s market capitalization now exceeds USD 40 billion as investors focus on sustained earnings momentum.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) is trading near the USD 511 mark as of September 18, 2026, supported by double digit second quarter 2026 growth and a higher full year earnings guidance confirmed in the latest earnings call on September 15, 2026.

Q2 2026 results show double digit growth

According to an earnings call summary reported by Choicestock on September 15, 2026, IDEXX Laboratories delivered earnings per share of USD 4.27 in the second quarter 2026, representing a 15 percent increase compared with the prior year period.

The same earnings call report from Choicestock indicates that IDEXX Laboratories’ management reiterated a target of roughly 10 percent revenue growth for fiscal year 2026, underscoring confidence in the company’s demand pipeline following strong Q2 2026 performance.

Raised full year guidance underpins investor sentiment

In the same coverage, Choicestock notes that IDEXX Laboratories raised its full year 2026 earnings guidance during the September 15, 2026 call, aligning the outlook with the 15 percent year over year EPS growth already achieved in the second quarter 2026.

This combination of around 10 percent expected revenue growth and 15 percent EPS growth for fiscal year 2026 positions IDEXX Laboratories as a solid earnings growth story in the veterinary diagnostics and animal health testing segment, which investors increasingly view as a structural growth market.

Stock trades near recent levels with sizeable market capitalization

Per market data from MarketScreener, IDEXX Laboratories stock closed at USD 511.68 on the Cboe venue on September 18, 2026, marking a 1.00 percent gain over the preceding five trading days and a 1.38 percent advance since the start of 2026.

According to a peer market capitalization overview from StockAnalysis, IDEXX Laboratories’ market capitalization stands at approximately USD 40.31 billion as of mid September 2026, highlighting the company’s scale within the broader life sciences and diagnostics universe.

Closing price and investor view

On its primary listing, IDEXX Laboratories stock was last reported at around USD 511.68 on September 18, 2026 on a US trading venue, a level that reflects investor willingness to pay a premium valuation for the company’s double digit earnings trajectory and raised fiscal year 2026 guidance.